Treatment of Early Immunoglobulin A Nephropathy by Angiotensin-converting Enzyme Inhibitor
|
|
- Lesley Walters
- 6 years ago
- Views:
Transcription
1 CLINICAL RESEARCH STUDY Treatment of Early Immunoglobulin A Nephropathy by Angiotensin-converting Enzyme Inhibitor Philip Kam-Tao Li, MD, Bonnie Ching-Ha Kwan, MBBS, Kai-Ming Chow, MBChB, Chi-Bon Leung, MBChB, Cheuk-Chun Szeto, MD Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China. ABSTRACT BACKGROUND: The treatment of immunoglobulin A (IgA) nephropathy with normal renal function and minimal proteinuria is unknown. METHODS: We randomly assigned 60 patients with IgA nephropathy, proteinuria 0.5 g/day, normal blood pressure and renal function to ramipril 2.5 mg daily or no treatment. Patients were followed for 5 years for the development of hypertension, proteinuria, or impaired renal function. RESULTS: The blood pressure of the treatment group was marginally lower than the control group throughout the study period. At 60 months, the event-free survival was marginally higher for the treatment group as compared with the control group (81.1% vs 70.5%, P.27). The proteinuria-free survival was similar at 82.9% and 79.3% for the treatment and control groups, respectively (P.6); hypertension-free survival was 86.4% and 79.3% (P.2). After 60 months of follow-up, the estimated glomerular filtration rate (GFR) was ml/min/1.73 m 2 for the treatment group and ml/min/1.73 m 2 for the control group (P.7), but the difference was not statistically significant. None of the patients developed impaired renal function. The rate of GFR decline was similar between the treatment and control groups ( vs ml/min/1.73 m 2 per year, respectively, P.7). In general, the study medication was well tolerated. Two patients needed to stop prematurely because of cough and dizziness. CONCLUSION: For early IgA nephropathy patients with minimal proteinuria, normal blood pressure, and normal renal function, treatment with 2.5 mg/daily of ramipril for 5 years does not offer any benefit Elsevier Inc. All rights reserved. The American Journal of Medicine (2013) 126, KEYWORDS: Chronic kidney disease; Proteinuria; Renin-angiotensin system Immunoglobulin A (IgA) nephropathy is the most common type of glomerulonephritis worldwide. 1 It causes end-stage renal disease in 15%-20% of individuals within 10 years of Funding: This study was supported in part by Sanofi-Aventis Pharma Hong Kong Limited, and the Chinese University of Hong Kong research accounts and The funding sources have no influence on the protocol development, data analysis, or preparation of this manuscript. Conflict of Interest: All authors have completed the Unified Competing Interest form and declare no other support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work. Authorship: All authors had access to the data and played a role in writing this manuscript. Requests for reprints should be addressed to Cheuk-Chun Szeto, MD, Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China. address: ccszeto@cuhk.edu.hk onset, 2,3 and in 30%-35% of individuals within 20 years of onset. Proteinuria, an elevated serum creatinine concentration, hypertension, and advanced, chronic disease in kidney biopsy predict progression. 4 Although patients who present with isolated hematuria, either macroscopic or microscopic, are often believed to have better prognoses, 5,6 recent data show that many of the patients develop hypertension and impaired renal function with time. 7 The treatment of IgA nephropathy with normal renal function and minimal proteinuria is unknown. Previous studies showed that angiotensin-converting enzyme (ACE) inhibitors reduce proteinuria 8-10 and retard the rate of decline of renal function in chronic proteinuric nephropathies, including IgA nephropathy There has been no study on treating early IgA nephropathy. In the present study, we evaluate the efficacy of the ACE inhibitor ramipril in the treatment of early IgA nephropathy /$ -see front matter 2013 Elsevier Inc. All rights reserved.
2 Li et al ACEI for Early IgAN 163 PATIENTS AND METHODS Patient Selection This was an open-label randomized controlled study. From February 2004 to September 2005, a total of 60 IgA nephropathy patients were recruited. We recruited patients who were Exclusion criteria were: expected survival 2 years; pregnant or nursing mother, or women of childbearing potential without an effective method of birth control; history of myocardial infarction, congestive heart failure, or any other medical indication that necessitates the use of ACE inhibitor; evidence of clinically significant hepatic, gastrointestinal, autoimmune disease; history of malignancy, drug or alcohol abuse; participation in any previous trial on ACE inhibitor; taking other investigational drugs within the past 30 days; history of noncompliance to medical regimens and patients who are considered potentially unreliable; or known history of sensitivity or allergy to ACE inhibitor. The study was approved jointly by the Chinese University of Hong Kong New Territories East Cluster Clinical Research Ethics Committee (ClinicalTrials.gov ID NCT ). aged between 18 and 65 years, had biopsy-confirmed IgA nephropathy, proteinuria 0.5 g per day, normal blood pressure, and serum creatinine below 120 mol/l. For all recruited patients, renal biopsy specimen was reviewed by pathologists by conventional methods. 4,14 CLINICAL SIGNIFICANCE Treatment Assignment After written informed consent, patients were randomized either to receive ramipril 2.5 mg daily or no treatment. Patients were randomized by a computer-generated list, which was generated and maintained by a third party that was not involved in the conduction of the study. The dosage of ramipril was maintained throughout the study period if there was no adverse effect. After recruitment, patients were followed at 4, 12, and 24 weeks, and then every 24 weeks for 5 years. During every visit, we measured body weight, blood pressure, pulse rate, renal function test, and proteinuria as quantified by spot urine for protein-to-creatinine ratio. Information about adverse events was collected by direct questioning and recorded. An adverse event was defined as any undesirable symptom or medical condition occurring after starting the study medication, whether considered drug related or not. For patients with early IgA nephropathy and minimal proteinuria, normal blood pressure and renal function, ramipril treatment for 5 years does not offer any benefit. A watchful waiting strategy should be adopted for patients with IgA nephropathy and proteinuria 0.5 g/day. Study End Point The primary end point of the study is any one of the following: 1) development of hypertension (defined as blood pressure above 140/90 mm Hg or the need of antihypertensive therapy); 2) development of proteinuria 1 g per day; and 3) 20% decline in the estimated glomerular filtration rate (GFR), which was computed by an equation validate in Chinese. 15 The slope of decline of the estimated GFRs also were compared. Sample Size Estimation The sample size was estimated by the Power Analysis and Sample Size for Windows software (PASS 2000, NCSS, Kaysville, Utah). We use the confidence interval theory to estimate the sample size. Based on our previous study, 7 proteinuria or hypertension develop in 40% of untreated patients in 5 years. On the other hand, prolonged ramipril therapy is expected to prevent the progression of chronic proteinuric nephropathies in approximately 50% of cases A one-sided log-rank test with an overall sample size of 60 subjects achieves, at a 0.05 significance level, detection of a difference of 0.2 between 0.6 and 0.8 the proportions surviving in groups 1 and 2, respectively. This corresponds to a hazard ratio of These results are based on the assumption that the hazard rates are proportional. Statistical Analysis Statistical analysis was performed by SPSS for Windows software version 15.0 (SPSS Inc., Chicago, Ill). Data were expressed in mean SD and analyzed on intention-to-treat basis. Data are compared by chi-squared test or Student s t-test as appropriate between treatment groups. Event-free survival was computed by the Kaplan-Meier analysis; the time to develop primary end point was compared by the log-rank test. A P value of below.05 was considered significant. All probabilities were 2-tailed. RESULTS We recruited 60 patients. Their baseline clinical and histological characteristics are summarized in Tables 1 and 2, respectively. None of the patients had been treated with corticosteroid or fish oil. The CONSORT flowchart is summarized in Figure 1. The blood pressure throughout the study period is summarized in Figure 2. In short, the treatment group had a significantly lower blood pressure than the control group (P.001 for both systolic and diastolic blood pressure), although the absolute difference in blood pressure between the groups was only modest. Primary End Point During the study period, 9 patients (3 men) of the treatment group and 11 of the control group (1 man) developed the
3 164 The American Journal of Medicine, Vol 126, No 2, February 2013 Table 1 Baseline Characteristics of the Recruited Patients Treatment Control P Value No. of patients Sex (M:F) 9:21 4:26.12 Age (years) Duration of disease (months) Body weight (kg) Blood pressure (mm Hg) Systolic Diastolic Serum creatinine (ìmol/l) egfr (ml/min/1.73 m 2 ) Urine protein (g:g-cr) egfr estimated glomerular filtration rate. primary end point. Patients who developed primary end point had a higher baseline proteinuria than those who did not ( vs g/day, P.002). There was no significant difference between age, baseline blood pressure, or estimated GFR between patients who did and did not develop primary end point (details not shown), and their histological characteristics also were similar (Table 2). Patients sex had no significant interaction with treatment group on the development of primary end point (P.6 for interaction). After 60 months of follow-up, the estimated GFR was ml/min/1.73 m 2 for the treatment group and ml/min/1.73 m 2 for the control group (P 0.7). At 60 months, the event-free survival was marginally higher for the treatment group as compared with the control group (81.1% vs 70.5%, P.266) (Figure 3), but the difference was not statistically significant. The rate of GFR decline was similar between the treatment and control groups ( vs ml/min/1.73 m 2 per year respectively, P.7). The cause of primary end point is compared between the groups and summarized in Table 3. At 60 months, the proteinuria-free survival was 82.9% and 79.3% for the treatment and control groups, respectively (P.636); the hypertension-free survival was 86.4% and 79.3% for the treatment and control groups, respectively (P.185) (Figure 4). None of the patients developed impaired renal function during the study period. Adverse Effects In general, the study medication was well tolerated. Among the treatment group, 3 patients reported cough and 2 reported dizziness. The study medication had to be stopped in 2 patients (one for each reason). No other major adverse effect was noted. In addition, 1 patient of the treatment group, and 2 of the control group, were lost to follow-up during the study period. DISCUSSION Although IgA nephropathy is the most common primary glomerulonephritis in the world, its best treatment remains undefined. For patients with minimal proteinuria and normal renal function, it remains unknown whether treatment is necessary. In this open-label randomized control trial, we found that treatment with 2.5 mg daily of ramipril, an ACE inhibitor, for 5 years offers very little, if any, benefit to patients with early IgA nephropathy. Our finding is consistent with previous studies on other chronic proteinuria nephropathy. 11,16 For example, the Ramipril Efficacy in Nephropathy (REIN) study found that patients with proteinuria of 2 g/day or greater gained the most benefit from ACE inhibitor treatment. 11 Similarly, the African American Study of Kidney Disease and Hypertension (AASK) Study found that ramipril, as compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria over 0.3 g/day. 16 It is important to realize that in the present study, we recruited patients with proteinuria below 0.5 g/day. To the best of our knowledge, there is no randomized control study that specifically targets patients with IgA nephropathy (or any other nondiabetic chronic proteinuric disease) and a proteinuria between 0.5 and 1.0 g/day. Further research is Table 2 Baseline Histological Characteristics* Treatment Control P Value No. of patients 30 (9) 30 (11) Morphologic score distribution.7 Grade I 26 (8) 27 (10) Grade II 4 (1) 3 (1) Prognostic score distribution Glomerular grading (GG).08 GG 1 29 (9) 30 (11) GG 2 1 (0) 0 Tubulointerstitial grading.3 (TIG) TIG 1 24 (6) 25 (10) TIG 2 7 (3) 4 (1) Hyaline arteriolosclerosis.3 (HA) Absent 22 (6) 25 (11) Present 8 (3) 5 (0) *Numbers in parentheses indicate the number of patients who developed primary end point. Determined in accordance with the classification by Haas, 4 taking into account the degree of mesangial proliferation, glomerular sclerosis, and tubular atrophy, on a scale of 1 to 5. Grade 1 indicates minimal histological changes, while grade 5 indicates advanced sclerosis and cortical tubular loss. Determined in accordance with the grading by To et al. 14 GG 1 mean sclerosis per glomerulus, 0% to 25%; GG 2 25% to 50%; and GG 3 50%. TIG 1 tubular atrophy and interstitial fibrosis were absent or in an area 5%; TIG 2 5% to 50%; and TIG 3 50%. HA was defined as the presence of arteriolar hyaline or proteinaceous exudation, with or without smooth muscle hyperplasia or luminal reduction.
4 Li et al ACEI for Early IgAN 165 Assessed for eligibility (n = 64) Excluded (n = 4) Not meeting inclusion criteria (n = 4) Randomized (n = 60) Allocated to intervention (n = 30) Received allocated intervention (n = 30) Allocated to observation only (n = 30) Lost to follow-up (give reasons) (n = 1) Discontinued intervention (n = 2) cough (n = 1) dizziness (n = 1) p Lost to follow-up (give reasons) (n = 2) Analysed (n = 30) Analy Analysed (n = 30) Figure 1 CONSORT flowchart of the study. Figure 2 Systolic and diastolic blood pressure throughout the study period. Open circles indicate the treatment group; closed circles indicate control group. Error bars represent SDs.
5 166 The American Journal of Medicine, Vol 126, No 2, February 2013 Figure 3 Kaplan-Meier estimate of event-free survival. necessary to determine whether treatment is beneficial in this group of patients. In the present study, around 30% of the control group developed hypertension or proteinuria, or both, during the 5-year study period. In general, hypertensive patients were treated with calcium channel blocker, with or without diuretics. The incidence of hypertension and proteinuria was similar to our previous report, 7 which found that around 40% of patients with early IgA nephropathy progressed to proteinuria or hypertension in 5 years. Furthermore, many of the patients in the present study had the disease for several years before being recruited for this study. It implies that despite a modest clinical presentation and long duration of stable condition, patients with IgA nephropathy have a continuous risk of disease progression and deserve regular monitoring. Our result, however, suggests that treatment with low-dose ACE inhibitor does not offer any benefit to this group of patients over a 5-year period of time. In general, ramipril treatment was well tolerated, and adverse effects were infrequent. Although 2 patients in the treatment group had premature termination of the study medication, their clinical follow-up was continued and data were included for the analysis. The overall result, however, remains similar if they are excluded for a per-protocol analysis (details not shown). Table 3 Primary End point of the Study s Treatment No. of patients Any primary end point 9 11* Hypertension 4 8 Proteinuria 5 6 Control *Three patients developed both hypertension and proteinuria. Figure 4 Kaplan-Meier estimate of: (A) proteinuria-free survival; and (B) hypertension-free survival. One potential bias of our study was that the study medicine, ramipril, may obscure the study end points (namely, the development of hypertension and proteinuria). Because the half-lives of ramipril and its major active metabolite ramiprilate, are around 12 hours, we routinely advised our patients to continue to take the morning dose of ramipril on the day before a clinic visit, omit the dose on the morning of visit, and had their blood pressure measured in the afternoon for the study purpose in order to minimize the direct blood pressure-lowering effect of ramipril. Nonetheless, the treatment group had a consistently lower blood pressure than the control group (by around 3 mm Hg). Although the difference was statistically significant, it remains uncertain whether such a small difference in blood pressure has any
6 Li et al ACEI for Early IgAN 167 clinical effect. Contrary to blood pressure lowering, the antiproteinuric effect of ramipril is more long lasting than its chemical half-life; we could not exclude the possibility that some of the proteinuria end points in the treatment group might have been masked. There are several limitations of our study. First, the sample size of the present study is small, and we may not have the sufficient statistical power to detect a treatment benefit. It is important to note that the sample size of this study was estimated a priori, with the assumption that proteinuria or hypertension developed in 40% of untreated patients in 5 years (as shown in our previous study 7 ), and ramipril therapy was expected to prevent the progression of chronic proteinuric nephropathies in approximately 50% of cases Based on these assumptions, a sample size of 60 subjects was expected to achieve an 80% statistical power with a significance level of.05. From the present study, around 30% of the control group and 20% of the treatment group progressed to proteinuria or hypertension. Based on these data, it is estimated that a total sample size of 630 would be necessary for 80% statistical power to detect the difference. It is of note that the detection of early IgA nephropathy depends on the renal biopsy criteria of individual centers and it may not be easy to have a large cohort of such patients worldwide for a randomized trial. Second, in the present study, we focused on proteinuria and hypertension, which are generally regarded as soft end points for chronic kidney disease. In fact, none of the patients in this study developed renal insufficiency during the follow-up, suggesting that the absolute risk of losing kidney function is low, and any treatment, even if effective in preventing hypertension or proteinuria, may not necessarily offer any benefit in protecting kidney function. In the present study, over 80% of the patients were female. The female preponderance agrees with our previous reports, especially among patients with hematuria and minimal proteinuria. 3,7 In theory, if female patients have a better prognosis, it would be difficult to demonstrate a treatment benefit. However, our previous study did not find that female sex has a lower risk of progression. 3 In addition, the present study was neither placebo-controlled nor double-blinded. It was possible that bias in assessment might be present. However, proteinuria and renal function are objective biochemical measures and the result should not be affected. In this study, blood pressures of all participating subjects were measured and recorded by paramedical staff who were unaware of the clinical record or treatment status of the patient. We believe the bias in blood pressure measurement also should be minimal. Another issue may be related to the drug dosage. We have used 2.5 mg ramipril, and whether an increased dose of 5 mg ramipril may have a different result can only be resolved by separate study. The recent Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Glomerulonephritis recommends long-term ACE inhibitor or angiotensin-receptor blocker (ARB) treatment when proteinuria is 1 g/day and suggests ACE inhibitor or ARB treatment if proteinuria is between 0.5 and 1 g/day. 17 There are no good data for patients with proteinuria 0.5 g/day. Our study is the first in a reasonably large cohort of IgA nephropathy patients with 5 years follow-up. Although this trial is seemingly a negative study, it does provide supporting evidence for the above KDIGO guidelines that the treatment with 2.5 mg daily of ramipril for this group of early IgA nephropathy patients with proteinuria 0.5 g/day does not provide additional benefit within a study period of 5 years. In trials using ARB in chronic IgA nephropathy, it has previously been shown to be of benefit. 18 Based on the result of our present study and the recent KDIGO guideline, 17 we suggest a watchful waiting strategy for patients with IgA nephropathy and proteinuria 0.5 g/day; ACE inhibitor or ARB treatment should be started if proteinuria is above this level. ACKNOWLEDGEMENTS We thank Ms. Lau Miu Fong and Ms. Cheng Mei-Shan Phyllis for their clerical support. This paper was presented in Abstract form at the American Society of Nephrology Kidney Week 2011 Annual Meeting, November in Philadelphia. The results presented in this paper have not been published previously in whole or part, except in Abstract format. References 1. D Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;245: D Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000; 36: Li PK, Ho KK, Szeto CC, Yu LM, Lai FM. Prognostic indicators of IgA nephropathy in Chinese clinical and pathological perspectives. Nephrol Dial Transplant. 2002;17: Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997;29: Galla JH. IgA nephropathy. Kidney Int. 1995;47: D Amico G, Ragni A, Gandini E, Fellin G. Typical and atypical natural history of IgA nephropathy. Contrib Nephrol. 1993;104: Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;110: Maschio G, Cagnoli L, Claroni F, et al. ACE inhibition reduce proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant. 1994; 9: Russo D, Pisani A, Balletta MM, et al. Additive anti-proteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis. 1999;33: Perico N, Remuzzi A, Sangalli F, et al. The antiproteinuria effect of angiotensin antagonsim in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol. 1998;9: Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis. 2000;35: Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet. 1998;352:
7 168 The American Journal of Medicine, Vol 126, No 2, February Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354: To KF, Choi PC, Szeto CC, et al. Outcome of IgA nephropathy in adults graded by chronic histological lesions. Am J Kidney Dis. 2000; 35: Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17: Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285: Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guideline for glomerulonephritis. Kidney Int. 2012;2(Suppl 2): Li PK, Leung CB, Chow KM, et al. Hong Kong study using Valsartan in IgA Nephropathy (HKVIN) a double-blind randomized placebocontrolled study. Am J Kidney Dis. 2006;47:
Reducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationManagement of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. Robert D. Toto, MD
R e v i e w P a p e r Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers Robert D. Toto, MD Both the prevalence and incidence of end-stage renal disease have been increasing
More informationDual Therapy with ACE Inhibitors and Angiotensin II Receptor Blockers in Proteinuric IgA Nephropathy Patients
Brief Communication Dual Therapy with ACE Inhibitors and Angiotensin II Receptor Blockers in Proteinuric IgA Nephropathy Patients Kai-Ming Chow, Cheuk-Chun Szeto, Bonnie Ching-Ha Kwan, Chi-Bon Leung, Kwok-Yi
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of steroid therapy GUIDELINES
Specific management of IgA nephropathy: role of steroid therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Steroid therapy may protect against progressive
More informationThe relation between elevated blood pressure (BP) and
ACE Inhibitors and Appearance of Renal Events in Hypertensive Nephrosclerosis Julián Segura, Carlos Campo, José L. Rodicio, Luis M. Ruilope Abstract Nephrosclerosis constitutes a major cause of end-stage
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More information(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)
[1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120
More informationEVIDENCE BASED TREATMENT OF IgA NEPHROPATHY. Jonathan Barratt
EVIDENCE BASED TREATMENT OF IgA NEPHROPATHY Jonathan Barratt EVIDENCE BASED TREATMENT OF IgA NEPHROPATHY We do not have much evidence EVIDENCE BASED TREATMENT OF IgA NEPHROPATHY We do not have much evidence.
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationEfficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
The new england journal of medicine original article Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency Fan Fan Hou, M.D., Ph.D., Xun Zhang, M.D., Guo Hua Zhang, M.D., Ph.D., Di
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES
Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of
More informationCurrent treatment recommendations in children with IgA nephropathy Selçuk Yüksel
Current treatment recommendations in children with IgA nephropathy Selçuk Yüksel Department of Pediatric Nephrology Pamukkale University School of Medicine IgA Nephropathy The most common cause of primary
More informationNephrology Grand Rounds. Mansi Mehta November 24, 2015
Nephrology Grand Rounds Mansi Mehta November 24, 2015 Case 51yo F with PMH significant for Hypertension referred to renal clinic for evaluation of elevated Cr. no known history of CKD; baseline creatinine
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationProceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009
www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers PROTEINURIA
More informationThe Seventh Report of the Joint National Commission
The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,
More informationOut of date SUGGESTIONS FOR CLINICAL CARE (Suggestions are based on level III and IV evidence)
Membranous nephropathy role of cyclosporine therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. The use of cyclosporine therapy alone to prevent progressive
More informationACEIs / ARBs NDHP dihydropyridine ( DHP ) ACEIs ARBs ACEIs ARBs NDHP. ( GFR ) 60 ml/min/1.73m ( chronic kidney disease, CKD )
005 16 175-180 1 1 ( chronic kidney disease, CKD ) 003 ( end-stage renal disease, ESRD ) Angiotensin-converting enzyme inhibitors ( ) angiotensin receptor blockers ( ) nondihydropyridine ( NDHP ) / NDHP
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of fish oil
Specific management of IgA nephropathy: role of fish oil Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Early and prolonged treatment with fish oil may retard
More informationLaunch Meeting 3 rd April 2014, Lucas House, Birmingham
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Launch Meeting 3 rd April 2014, Lucas House, Birmingham Prof Sunil Bhandari
More informationANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.
ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN
More informationMinimal change nephropathy: an update (for adults) Dr. CC Szeto Department of Medicine & Therapeutics The Chinese University of Hong Kong
Minimal change nephropathy: an update (for adults) Dr. CC Szeto Department of Medicine & Therapeutics The Chinese University of Hong Kong First, it is not uncommon Cameron JS. Am J Kidney Dis 10: 157 171,
More informationThe nephrotic syndrome defined as urinary protein
Original Article Comparative Study of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker in the Treatment of Steroid-Resistant Idiopathic Nephrotic Syndrome NS Kumar*, AK Singh*, RN Mishra**,
More informationRemission and Regression of Diabetic Nephropathy
515 Review Remission and Regression of Diabetic Nephropathy Hirofumi MAKINO, Yoshio NAKAMURA, and Jun WADA Diabetic nephropathy has become the single largest cause of end-stage renal disease (ESRD) worldwide.
More informationGrading of Acute and Chronic Renal Lesions in Henoch- Schönlein Purpura
Grading of Acute and Chronic Renal Lesions in Henoch- Schönlein Purpura Cheuk Chun Szeto, M.R.C.P., Paul C.L. Choi, F.R.C.P.A., Ka Fai To, F.R.C.P.A., Philip K.T. Li, F.R.C.P., Joannie Hui, F.R.A.C.P.,
More informationClinico-pathological features of kidney disease in diabetic cases
https://doi.org/10.1007/s10157-018-1556-4 INVITED REVIEW ARTICLE Clinico-pathological features of kidney disease in diabetic cases Kengo Furuichi 1 Miho Shimizu 1 Hirokazu Okada 2 Ichiei Narita 3 Takashi
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationThe hypertensive kidney and its Management
The hypertensive kidney and its Management Dr H0 Chung Ping Hypertension Management Seminar 20061124 Hypertensive kidney Kidney damage asymptomatic till late stage Viscous cycle to augment renal damage
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationIgA-Nephropathy: an update on treatment Jürgen Floege
IgA-Nephropathy: an update on treatment Jürgen Floege Division of Nephrology & Immunology juergen.floege@rwth-aachen.de Floege & Feehally, Nat Rev Nephrol 2013 Floege & Eitner, J Am Soc Nephrol. 2011 If
More informationCitation Acta medica Nagasakiensia. 2003, 48
NAOSITE: Nagasaki University's Ac Title Author(s) Renal Outcome of Immunoglobulin A N Horita, Yoshio; Tadokoro, Masato; T Miyazaki, Masanobu; Taguchi, Takash Yoshiyuki; Kohno, Shigeru Citation Acta medica
More informationNo effect of enalapril on progression in autosomal dominant polycystic kidney disease
Nephrol Dial Transplant (2003) 18: 2314 2320 DOI: 10.1093/ndt/gfg417 Original Article No effect of enalapril on progression in autosomal dominant polycystic kidney disease Marjan A. van Dijk 1, Martijn
More informationCHAPTER 4. Paediatric Renal Biopsies
2nd Report of the Malaysian Registry of Renal Biopsy 2008 PAEDIATRIC RENAL BIOPSIES CHAPTER 4 Paediatric Renal Biopsies Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Wan Jazilah Wan Ismail Yap Yok Chin
More informationEffect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial
Int Urol Nephrol (2012) 44:1763 1770 DOI 10.1007/s11255-011-0110-z NEPHROLOGY ORIGINAL PAPER Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised,
More informationCase Report Corticosteroids in Patients with IgA Nephropathy and Severe Chronic Renal Damage
Case Reports in Nephrology Volume, Article ID 89, pages doi:.//89 Case Report Corticosteroids in Patients with IgA Nephropathy and Severe Chronic Renal Damage Claudio Pozzi, Francesca Ferrario, Bianca
More informationHasan Fattah 3/19/2013
Hasan Fattah 3/19/2013 AASK trial Rational: HTN is a leading cause of (ESRD) in the US, with no known treatment to prevent progressive declines leading to ESRD. Objective: To compare the effects of 2 levels
More informationSpringerLink Header: Hypertension (WB White and AJ Peixoto, Section
SpringerLink Header: Hypertension (WB White and AJ Peixoto, Section Editors) What Are Optimal Blood Pressure Targets for Patients with Hypertension and Chronic Kidney Disease? Gopesh K. Modi, MD DM 1,
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21978 holds various files of this Leiden University dissertation. Author: Goeij, Moniek Cornelia Maria de Title: Disease progression in pre-dialysis patients:
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationCHAPTER 2. Primary Glomerulonephritis
2nd Report of the PRIMARY GLOMERULONEPHRITIS CHAPTER 2 Primary Glomerulonephritis Sunita Bavanandan Lee Han Wei Lim Soo Kun 21 PRIMARY GLOMERULONEPHRITIS 2nd Report of the 2.1 Introduction This chapter
More informationProf. Rosanna Coppo Director of the Nephrology, Dialysis and Transplantation Department Regina Margherita Hospital Turin, Italy. Slide 1.
ROLE OF PATHOLOGY AND CLINICAL FEATURES IN PREDICTING PROGRESSION OF IGA NEPHROPATHY: RESULTS FROM THE ERA-EDTA RESEARCH VALIGA Rosanna Coppo, Turin, Italy Chairs: François Berthoux, Saint-Etienne, France
More informationValidation of the Oxford Classification of IgA Nephropathy: A Single-Center Study in Korean Adults
original article korean j intern med 202;27:293-300 pissn 226-3303 eissn 2005-6648 Validation of the Oxford Classification of IgA Nephropathy: A Single-Center Study in Korean Adults Hoyoung Lee, Sul Hee
More informationChapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org & 2012 KDIGO Chapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, 172 176; doi:10.1038/kisup.2012.17 INTRODUCTION This
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationProf. Armando Torres Nephrology Section Hospital Universitario de Canarias University of La Laguna Tenerife, Canary Islands, Spain.
Does RAS blockade improve outcomes after kidney transplantation? Armando Torres, La Laguna, Spain Chairs: Hans De Fijter, Leiden, The Netherlands Armando Torres, La Laguna, Spain Prof. Armando Torres Nephrology
More informationPreventing kidney failure: Primary care physicians must intervene earlier
REVIEW CME CREDIT CHRISTOPHER J. HEBERT, MD Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio Preventing kidney failure: Primary care physicians must intervene earlier ABSTRACT Mild chronic kidney
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationOriginal Investigation
Research Original Investigation Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients With Predialysis Advanced Chronic Kidney Disease, Hypertension, and Anemia Ta-Wei Hsu,
More informationACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence?
Reviews ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence? George L. Bakris, MD; 1 and Matthew Weir, MD 2 Although angiotensin-converting
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationThe organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.
The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Outline &
More informationEffective Health Care Program
Comparative Effectiveness Review Number 37 Effective Health Care Program Chronic Kidney Disease Stages 1 3: Screening, Monitoring, and Treatment Executive Summary Objectives This systematic review evaluates
More informationCase Studies: Renal and Urologic Impairments Workshop
Case Studies: Renal and Urologic Impairments Workshop Justine Lee, MD, DBIM New York Life Insurance Co. Gina Guzman, MD, DBIM, FALU, ALMI Munich Re AAIM Triennial October, 2012 The Company You Keep 1 Case
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationInternal Medicine ( ) 51 巻 11 号 :1323~1328.
Internal Medicine (2012.01) 51 巻 11 号 :1323~1328. Retrospective Comparison of the Efficacy of Tonsillectomy with and without Steroid-pulse Therapy in IgA Nephropathy Patients. Nakagawa Naoki, Kabara Maki,
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationC URRENT T HERAPEUTIC R ESEARCH. 94 Copyright 2007 Excerpta Medica, Inc. Reproduction in whole or part is not permitted.
C URRENT T HERAPEUTIC R ESEARCH V OLUME 68, NUMBER 2, MARCH/APRIL 27 Anti-Albuminuric Effect of Losartan Versus Amlodipine in Hypertensive Japanese Patients with Type 2 Diabetes Mellitus: A Prospective,
More informationGlomerular pathology in systemic disease
Glomerular pathology in systemic disease Lecture outline Lupus nephritis Diabetic nephropathy Glomerulonephritis Associated with Bacterial Endocarditis and Other Systemic Infections Henoch-Schonlein Purpura
More informationRenal replacement therapy for patients with diabetes mellitus in Hong Kong
Hong Kong J Journal Nephrol of 2001;3(2):89-96. Nephrology 2001;3(1):89-96. Y CHOY, et al R E N L REGISTRY Renal replacement therapy for patients with diabetes mellitus in Hong Kong o-ying CHOY 1, Yiu-Wing
More informationHypertension is an important global public
IN THE LITERATURE Blood Pressure Target in Individuals Without Diabetes: What Is the Evidence? Commentary on Verdecchia P, Staessen JA, Angeli F, et al; on behalf of the Cardio-Sis Investigators. Usual
More informationKeywords albuminuria, hypertension, nephropathy, proteinuria
Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Rigas G. Kalaitzidis and George L. Bakris Department of Medicine, Hypertensive Diseases
More informationNephrotic syndrome minimal change disease vs. IgA nephropathy. Hadar Meringer Internal medicine B Sheba
Nephrotic syndrome minimal change disease vs. IgA nephropathy Hadar Meringer Internal medicine B Sheba The Case 29 year old man diagnosed with nephrotic syndrome 2 weeks ago and complaining now about Lt.flank
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationProtecting the kidneys in lupus nephritis
Review Protecting the kidneys in lupus nephritis Kidney involvement is common in systemic lupus erythematosus. The inciting event in lupus nephritis is immune complex accumulation in the kidneys. While
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOptimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationUniversity of Groningen. Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste
University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationNephrology. Safety and Tolerability of High-Dose Angiotensin Receptor Blocker Therapy in Patients with Chronic Kidney Disease: A Pilot Study
American Journal of Nephrology Original Report: Patient-Oriented, Translational Research Am J Nephrol 2004;24:340 345 DOI: 10.1159/000078950 Received: March 8, 2004 Accepted: April 5, 2004 Published online:
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationRandom forest can accurately predict the development of end-stage renal disease in immunoglobulin a nephropathy patients
Original Article Page 1 of 8 Random forest can accurately predict the development of end-stage renal disease in immunoglobulin a nephropathy patients Xin Han 1#, Xiaonan Zheng 2#, Ying Wang 3, Xiaoru Sun
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationPrimary Care Approach to Management of CKD
Primary Care Approach to Management of CKD This PowerPoint was developed through a collaboration between the National Kidney Foundation and ASCP. Copyright 2018 National Kidney Foundation and ASCP Low
More informationof IgA nephropathy: a systematic review
Original Article Singapore Med12008,49(10):780 Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review Tan C H R, Loh P T, Yang W S, Chan C M ABSTRACT Introduction: The aim of this
More informationModeration of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers
original article http://www.kidney-international.org & 212 International Society of Nephrology see commentary on page 257 Moderation of dietary sodium potentiates the renal and cardiovascular protective
More informationClinical outcomes, when matched at presentation, do not vary between adult-onset Henöch-Schönlein purpura nephritis and IgA nephropathy
http://www.kidney-international.org & 2012 International Society of Nephrology Clinical outcomes, when matched at presentation, do not vary between adult-onset Henöch-Schönlein purpura nephritis and IgA
More informationACP Brief Fall 2006 prioritization. Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF)
ACP Brief Fall 2006 prioritization Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF) Background This topic was submitted by BC PharmaCare during
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More information신장환자의혈압조절 나기영. Factors involved in the regulation of blood pressure
신장환자의혈압조절 K/DOQI Clinical practice guidelines on Hypertension and Antihypertensive agents in CKD 나기영 Factors involved in the regulation of blood pressure Renal function curve MAP (mmhg) Central role of
More informationKerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009
Kerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009 DR. KERRY COOPER IS ON THE SPEAKER BUREAU OF AMGEN, ABBOTT, GENZYME, SHIRE, AND BMS DR. COOPER IS ALSO INVOLVED IN CLINICAL
More informationArticle. The Use of the Oxford Classification of IgA Nephropathy to Predict Renal Survival
Article The Use of the Oxford Classification of IgA Nephropathy to Predict Renal Survival Eric Alamartine,* Catherine Sauron,* Blandine Laurent, Aurore Sury,* Aline Seffert,* and Christophe Mariat* Summary
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationClinical prognostic factors in biopsy-proven benign nephrosclerosis
Nephrol Dial Transplant (2003) 18: 517 523 Original Article Clinical prognostic factors in biopsy-proven benign nephrosclerosis Bjørn Egil Vikse 1, Knut Aasarød 3, Leif Bostad 2 and Bjarne M. Iversen 1
More informationThe impact of stopping inhibitors of the renin angiotensin system in patients with advanced chronic kidney disease
NDT Advance Access published October 10, 2009 Nephrol Dial Transplant (2009) 1 of 6 doi: 10.1093/ndt/gfp511 Original Article The impact of stopping inhibitors of the renin angiotensin system in patients
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationProteinuria increases the risk for progression of chronic. Review
Review Annals of Internal Medicine Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin Angiotensin System on Proteinuria in Renal Disease Regina Kunz, MD, MSc(Epi);
More informationBlocking the renin-angiotensin system (RAS) would be
Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin
More informationUniversity of Groningen. Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste
University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationDevelopment of Renal Disease in People at High Cardiovascular Risk: Results of the HOPE Randomized Study
J Am Soc Nephrol 14: 641 647, 2003 Development of Renal Disease in People at High Cardiovascular Risk: Results of the HOPE Randomized Study JOHANNES F. E. MANN, HERTZEL C. GERSTEIN, QI-LONG YI, EVA M.
More informationThe Remission Clinic approach to halt the progression of kidney disease
THOROUGH CRITICAL APPRAISAL JN EPHROL 24( DOI:10.5301/JN.2011.7763 The Remission Clinic approach to halt the progression of kidney disease The Remission Clinic Task Force * 1, 2, Clinical Research Center
More informationGlomerular tip adhesions predict the progression of IgA nephropathy
Maeda et al. BMC Nephrology 2013, 14:272 RESEARCH ARTICLE Open Access Glomerular tip adhesions predict the progression of IgA nephropathy Kunihiro Maeda 1, Shogo Kikuchi 2, Naoto Miura 1, Keisuke Suzuki
More information